C-16G2 is under clinical development by Armata Pharmaceuticals and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect C-16G2’s likelihood of approval (LoA) and phase transition for Dental Caries took place on 27 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their C-16G2 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

C-16G2 overview

C-16G2 is under development for the prevention of Streptococcus mutans sustained dental caries. The drug candidate is administered through oral route as a  gel and mouth rinse. The C-16G2 peptide consists of two functional regions: an S. mutans-selective targeting region comprised of a fragment of the S. mutans competence stimulating peptide (CSP); and a broad-spectrum antimicrobial peptide (G2).  The drug candidate is developed based on selectively targeted antimicrobial peptides (STAMPs) technology.

Armata Pharmaceuticals overview

Armata Pharmaceuticals, formerly AmpliPhi Biosciences Corp, is a biotechnology company. It develops pathogen-specific bacteriophage drugs for the treatment of antibody-resistant bacterial infections. The company is investigating AP-PA02 drug against cystic fibrosis and non-CF bronchiectasis; and AP-PA03 to treat pneumonia. The company is also evaluating AP-SA02 program for the treatment of staphylococcus aureus infections such as bacteremia and periprosthetic joint infections (PJI). Armata Pharmaceuticals utilizes its proprietary synthetic phage platform to develop therapies for multidrug-resistant bacterial infections. It works in partnership with Merck & Co Inc to develop its products. Armata Pharmaceuticals is headquartered in Marina del Rey, California, the US.

Quick View C-16G2 LOA Data

Report Segments
  • Innovator
Drug Name
  • C-16G2
Administration Pathway
  • Oral
Therapeutic Areas
  • Mouth and Dental Disorders
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.